Nevirapine reduced mother-to-child transmission better than AZT--at 70 times less the cost.
A follow-up of a Uganda study shows that a single dose of nevirapine to the mother in labor and a single dose to the infant shortly after birth continues to show excellent results when the infants reach 18 months--despite breast feeding for 99% of the infants, and some HIV transmission that occurred as a result.
D016527:Drug Costs; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000635:transmission*; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D019829:Nevirapine / Q000191:economics / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D018894:Reverse Transcriptase Inhibitors / Q000191:economics / Q000627:therapeutic use*; D015215:Zidovudine / Q000191:economics / Q000627:therapeutic use*
D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D019829:Nevirapine